<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79058">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02068846</url>
  </required_header>
  <id_info>
    <org_study_id>12-0036</org_study_id>
    <secondary_id>1R21DE023046-01A1</secondary_id>
    <nct_id>NCT02068846</nct_id>
  </id_info>
  <brief_title>BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent</brief_title>
  <official_title>BK Virus in Salivary Gland Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze BK viral infection in salivary gland diseases;
      specifically, to determine a definitive relationship between BK Virus and HIV associated
      salivary gland disease (HIVSGD).  Participants are adults HIV+SGD+ who will be randomized
      1:1 to receive BK Virus antiviral (ciprofloxacin) or placebo for 28 days.  Salivary
      function/protein secretion will be correlated with BK polyomavirus titers.  We expect that
      patients with HIV+SGD+ will have elevated oral BK polyomavirus viral loads and will benefit
      from Ciprofloxacin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>(BK) Virus replication and shedding</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>It has been  determined that patients with (HIVSGD) shed high levels of (BK) Virus and have evidence of replicating (BK) Virus in their salivary gland tissues. Body fluids and salivary gland tissue will be assessed for evidence of (BK) Virus replication.  It will be determine whether Cipro administration decreases (BK) Virus replication in patients with (HIVSGD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Salivary function</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>It will be determine whether salivary gland function is improved or restored with the administration of Cipro.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV</condition>
  <condition>Salivary Gland Disease</condition>
  <condition>Benign Lymphoepithelial Lesion</condition>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>over encapsulated, 500mg bid, 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Over encapsulated to match active comparator, bid, 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>20 (SGDHIV) Participants will be randomized to either Ciprofloxacin or a Placebo arm. Ciprofloxacin 500mg will be over encapsulated and taken 2x daily for 28days, Placebo will also be over encapsulated and taken 2x daily for 28days. This study is double blinded. Each study participant will be consented and be required to complete study questionnaires.</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <other_name>Cipro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV positive with Salivary Gland Disease

          -  Ability to read and understand English

        Exclusion Criteria:

          -  Allergy to the family of fluoroquinolones (including ciprofloxacin)

          -  Currently taking tizanidine

          -  Concurrently taking antiacids containing magnesium hydroxide or aluminum hydroxide

          -  Current use of Theophylline

          -  Previous tendon disorder such as Rheumatoid arthritis

          -  History of seizures

          -  Current use of phenytoin

          -  Current use of glyburide

          -  Current use of methotrexate

          -  Severe renal impairment (known creatinine clearance &lt; 30 or on dialysis)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Webster-Cyriaque, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of North Carolina School of Dentistry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jo-Ann A Blake, RDH, MPH</last_name>
    <phone>919 537-3361</phone>
    <email>jo-ann_blake@unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Webster-Cyriaque, DDS, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of North Carolina School of Dentistry</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jennifer Webster-Cyriaque, DDS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>February 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Jennifer Webster-Cyriaque, DDS, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Salivary Gland Disease</keyword>
  <keyword>Benign Lymphoepithelial Lesion</keyword>
  <keyword>BK Polyomavirus</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Salivary Gland Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
